Altamira Therapeutics Ltd. (EARS) Stock Analysis
DELISTED 2021
What happened to Altamira Therapeutics Ltd. (EARS) stock?
Altamira Therapeutics Ltd. (EARS) no longer trades on public markets. It was delisted in July 2021. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- July 2021
- Last recorded price (historical):
- $3.05 (last quote on record before the July 2021 delisting; historical, not a current quote)
Market cap $4.21M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Altamira Therapeutics Ltd. (EARS). Altamira Therapeutics Ltd. is a biopharmaceutical company focused on developing treatments for neurotology and central nervous system disorders. Their pipeline includes therapies for hearing loss, tinnitus, vertigo, and antipsychotic-induced weight gain.
Last analyzed: Mar 18, 2026Altamira Therapeutics Ltd. (EARS) Healthcare & Pipeline Overview
More about this archive record
Can I still buy EARS shares?
No. EARS stopped trading on public markets in July 2021, so the shares are not available through a broker. Anything you see quoted for EARS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before EARS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Altamira Therapeutics Ltd.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.